Skin Conditions & Dermatology Clinical Trials Update: Week 16, 2026

Published April 17, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

This Phase 3 trial is testing remibrutinib, a new oral medication, in adolescents with chronic spontaneous urticaria (CSU) who do not respond well to standard antihistamines. If successful, this treatment could offer young patients better symptom control and improve their quality of life. The study includes a 24-week treatment period and offers optional long-term follow-up for safety and effectiveness.

Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo

This Phase 4 study is examining CABTREO, a topical gel that combines three active ingredients, for children aged 9 to 11 years with acne vulgaris. By testing safety and effectiveness in this younger age group, the study aims to provide a new treatment option that could better manage acne symptoms early on. The results will help guide future pediatric acne therapies.

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

This Phase 3 trial is evaluating ESK-001, an oral drug, in adults with moderate to severe plaque psoriasis. The study includes over 860 participants and compares ESK-001 to placebo and other active treatments. If effective, it could offer a new oral option to reduce symptoms and improve daily life for people living with this chronic skin condition.

A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

This Phase 4 study compares two systemic treatments, risankizumab and deucravacitinib, in adults with moderate plaque psoriasis who have not previously used biologic therapies. The trial aims to find out which treatment offers better safety and symptom relief, potentially expanding options for people needing whole-body treatment. Over 390 participants are involved across several countries.

A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis

This Phase 4 trial is focused on children aged 6 to under 15 with moderate-to-severe atopic dermatitis. It studies the long-term effects of dupilumab on skin barrier function, which is important for managing this chronic condition. Understanding these effects may help improve treatment strategies and outcomes for pediatric patients.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.